TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07111520: A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Sponsor: BioNTech SE · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 880 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$8,285,970

Rescue Site Savings

+$5,458,530

Unlock Full NCT07111520 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07111520 Rescue Dossier →